<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="132565">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01376115</url>
  </required_header>
  <id_info>
    <org_study_id>112279</org_study_id>
    <nct_id>NCT01376115</nct_id>
  </id_info>
  <brief_title>Drug Use Investigation for ARRANON G (Nelarabine) Injection 250mg</brief_title>
  <official_title>Drug Use Investigation for ARRANON G (Nelarabine) Injection 250mg</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate safety and efficacy on Japanese subjects treated with nelarabine injection
      for intravenous use in clinical settings of the following diseases:

        1. T-cell acute lymphocytic leukemia (T-ALL)

        2. T-cell lymphoblastic lymphoma (T-LBL) Also, &quot;any adverse events involving neurological
           disorder, hypotension, and blood disorder and their details&quot; are to be investigated as
           an item of particular concern. In addition, subject outcome (alive or dead) at one year
           after the start of treatment will also be investigated.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 18, 2008</start_date>
  <completion_date type="Anticipated">August 18, 2017</completion_date>
  <primary_completion_date type="Anticipated">August 18, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The number of adverse events in Japanese subjects treated with nelarabine based on prescribing information under the conditions of general clinical practice.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Any incidence of adverse events related to neurological disorder, hypotension, and blood disorder and their details</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Outcome (alive or dead) at one year after the start of treatment</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Subjects administered nelarabine</arm_group_label>
    <description>Subjects with T-cell acute lymphocytic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LBL) prescribed nelarabine during study period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nelarabine</intervention_name>
    <arm_group_label>Subjects administered nelarabine</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects with the following diseases in Japanese adults and children

          1. T-cell acute lymphocytic leukemia (T-ALL)

          2. T-cell lymphoblastic lymphoma (T-LBL)
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of T-cell acute lymphocytic leukemia (T-ALL) or T-cell lymphoblastic
             lymphoma (T-LBL)

        Exclusion Criteria:

          -  Subjects with hypersensitivity to nelarabine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone_ext>+41613241111</phone_ext>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Tsukuba Hospital</name>
      <address>
        <city>Tsukuba</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <lastchanged_date>April 5, 2017</lastchanged_date>
  <firstreceived_date>June 16, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
